Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

429 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial.
Morgan RD, Clamp AR, White DJ, Price M, Burghel GJ, Ryder WDJ, Mahmood RD, Murphy AD, Hasan J, Mitchell CL, Salih Z, Wheeler C, Buckley E, Truelove J, King G, Ainaoui Y, Bhaskar SS, Shaw J, Evans DGR, Kilerci B, Pearce SP, Brady G, Dive C, O'Connor JPB, Wallace AJ, Rothwell DG, Edmondson RJ, Jayson GC. Morgan RD, et al. Among authors: dive c. Clin Cancer Res. 2023 Jul 14;29(14):2602-2611. doi: 10.1158/1078-0432.CCR-22-3282. Clin Cancer Res. 2023. PMID: 36799931
Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.
Cummings J, Ranson M, Lacasse E, Ganganagari JR, St-Jean M, Jayson G, Durkin J, Dive C. Cummings J, et al. Among authors: dive c. Br J Cancer. 2006 Jul 3;95(1):42-8. doi: 10.1038/sj.bjc.6603220. Br J Cancer. 2006. PMID: 16804528 Free PMC article.
Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy.
Mitchell CL, O'Connor JPB, Jackson A, Parker GJM, Roberts C, Watson Y, Cheung S, Davies K, Buonaccorsi GA, Clamp AR, Hasan J, Byrd L, Backen A, Dive C, Jayson GC. Mitchell CL, et al. Among authors: dive c. Ann Oncol. 2010 Oct;21(10):1982-1989. doi: 10.1093/annonc/mdq079. Epub 2010 Mar 29. Ann Oncol. 2010. PMID: 20351070 Free article.
A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours.
Horsley L, Cummings J, Middleton M, Ward T, Backen A, Clamp A, Dawson M, Farmer H, Fisher N, Halbert G, Halford S, Harris A, Hasan J, Hogg P, Kumaran G, Little R, Parker GJ, Potter P, Saunders M, Roberts C, Shaw D, Smith N, Smythe J, Taylor A, Turner H, Watson Y, Dive C, Jayson GC; Cancer Research UK Drug Development Office Phase I clinical trial. Horsley L, et al. Among authors: dive c. Cancer Chemother Pharmacol. 2013 Dec;72(6):1343-52. doi: 10.1007/s00280-013-2320-9. Epub 2013 Oct 20. Cancer Chemother Pharmacol. 2013. PMID: 24141375 Clinical Trial.
429 results